Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrogen for cGVHD
NCT02918188Phase 2Recruiting
- Start
- Jan 2016
- Primary completion
- Jan 2026
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Molecular hydrogen in chronic graft-versus-host disease (cGVHD). Primary endpoint: Overall Response Rate at 12 months. Started Jan 2016; status: recruiting.
02
Drugs
Molecular hydrogen
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT02918188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02918188.